CoChat

Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients

Open access
Aasebø, Kristine Ø., Dragomir, Anca, Sundström, Magnus, Mezheyeuski, Artur, Edqvist, Per‐Henrik, Eide, Geir Egil, Ponten, Fredrik, Pfeiffer, Per, Glimelius, Bengt, Sorbye, Halfdan · 2019 · Cancer Medicine
Cited by 51

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Immunotherapy for patients with microsatellite‐instable (MSI‐H) tumors or BRAF‐inhibitors combination treatment for BRAF‐mutated (mut BRAF) tumors in metastatic colorectal cancer (mCRC) is promising, but the frequency of these molecular changes in trial patients are low. Unselected population‐based studies of these molecular changes are warranted. Methods: A population‐based cohort of 798 mCRC patients in Scandinavia was studied. Patient and molecular tumor characteristics, overall survival (OS) and progression‐free survival (PFS) were estimated. Results: Here, 40/583 (7%) tumor samples were MSI‐H and 120/591 (20%) were mut BRAF; 87% of MSI‐H tumors were mut BRAF (non‐Lynch). Elderly (>75 years) had more often MSI‐H (10% vs 6%) and MSI‐H/mut BRAF (9% vs 4%) tumors. Response rate (5% vs 44%), PFS (4 vs 8 months), and OS (9 vs 18 months) after first‐line chemotherapy was all significantly lower in patients with MSI‐H compared to patients with microsatellite stable tumors. MSI‐H and mut BRAF were both independent poor prognostic predictors for OS (P = 0.049, P < 0.001) and PFS (P = 0.045, P = 0.005) after first‐line chemotherapy. Patients with MSI‐H tumors received less second‐line chemotherapy (15% vs 37%, P = 0.005). Conclusions: In unselected mCRC patients, MSI‐H and mut BRAF cases were more common than previously reported. Patients with MSI‐H tumors had worse survival, less benefit from chemotherapy, and they differed considerably from recent third‐line immunotherapy trial patients as they were older and most had mut BRAF tumor (non‐Lynch).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.2205

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 51

Metadata

Authors
Aasebø, K. Ø., Dragomir, A., Sundström, M., Mezheyeuski, A., Edqvist, P., Eide, G. E., Ponten, F., Pfeiffer, P., Glimelius, B., & Sorbye, H.
Venue
Cancer Medicine
Publisher
Wiley
Published
2019-05-09
Volume
8
Issue
7
Pages
3623-3635
ISSN
2045-7634 (ISSN-L)
OpenAlex
W2944646623
Cited by
51
References
5
FWCI
2.90
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.